Cellosaurus logo
expasy logo

Cellosaurus 166-32 (CVCL_B0NC)

[Text][XML][JSON]
Cell line name 166-32
Accession CVCL_B0NC
Resource Identification Initiative To cite this cell line use: 166-32 (RRID:CVCL_B0NC)
Comments Group: Patented cell line.
Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12476.
Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized Fab antigen binding domain of the therapeutic antibody lampalizumab (FCFD4514S; RG7417) which was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration.
Monoclonal antibody isotype: IgG1, kappa.
Monoclonal antibody target: UniProtKB; P00746; Human CFD.
Species of origin Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Hierarchy Parent: CVCL_2199 (Sp2/0-Ag14)
Category Hybridoma
Publications

PubMed=10456004; DOI=10.1016/S0041-1345(99)00297-3
Elaine J. Tanhehco, Kenneth S. Kilgore, David Austin Liff, Kerri Lynn Murphy, Michael Sek-Chung Fung, William Nai-Chau Sun, Cecily Rou-Yun Sun, Benedict Robert Lucchesi;
The anti-factor D antibody, MAb 166-32, inhibits the alternative pathway of the human complement system.
Transplant. Proc. 31:2168-2171(1999)

Patent=US6956107
Michael Sek-Chung Fung, William Nai-Chau Sun, Cecily Rou-Yun Sun;
Inhibitors of complement activation.
Patent number US6956107, 18-Oct-2005

Cross-references
Cell line collections (Providers) ATCC; HB-12476
Encyclopedic resources Wikidata; Q108819399
Entry history
Entry creation23-Sep-2021
Last entry update21-Mar-2023
Version number4